November 29, 2022Open Access

Genetic Heterogeneity, Tumor Microenvironment and Immunotherapy in Triple-Negative Breast Cancer

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

inhibitors, cancer vaccines, or natural killer cell therapy. Targeted therapies may improve therapeutic response, eliminate therapeutic resistance, and improve overall patient survival. In the future, these evolving advancements should be implemented for personalized medicine and state-of-art management of cancer patients.

Me gusta

Guardar

Ver artículo completo

Cite This Study

Kúdelová et al. (Tue,) studied this question.

synapsesocial.com/papers/6a0132c8da5c1eb07f2dd060 https://doi.org/https://doi.org/10.3390/ijms232314937

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Ancestry-specific gene expression profiles in TNBC tumors.2020 · 1 citations
2Calculated Tumor-Associated Neutrophils Are Associated with the Tumor—Stroma Ratio and Predict a Poor Prognosis in Advanced Gastric Cancer2022 · 22 citations
3<p>Long Noncoding RNA RP11-334E6.12 Promotes the Proliferation, Migration and Invasion of Breast Cancer Cells Through the EMT Pathway by Activating the STAT3 Cascade</p>2020 · 6 citations
4Identification and validation of a combined hypoxia and immune index for triple‐negative breast cancer2020 · 90 citations
5The journey of tumor-infiltrating lymphocytes as a biomarker in breast cancer: clinical utility in an era of checkpoint inhibition2021 · 271 citations

Me gusta

Guardar

Ver artículo completo